journal article·2021-02

Nitrogen-containing bisphosphonate-loaded micro-arc oxidation coating for biodegradable magnesium alloy pellets inhibits osteosarcoma through targeting of the mevalonate pathway

Mei Li, Mengyu Yao, Weidan Wang, Peng Wan, Xiao Chu, Yufeng Zheng, Ke Yang, Yu Zhang

Acta Biomaterialia· Volume 121
Publisher page

Abstract

Osteosarcoma (OS) remains one of the most threatening primary malignant human tumors of the bone, especially in the first or second decade of life. Unfortunately, the clinical therapeutic efficacy has not substantially improved over the past four decades. Therefore, to achieve efficient tumor eradication, a new approach to prevent tumor recurrence is urgently needed. Here, we develop a new bisphosphonate (BP)-loaded microarc oxidation (MAO) coated magnesium-strontium (Mg-Sr) alloy pellet that can inhibit OS, and we illuminate the cellular and molecular mechanisms of the inhibiting effect. To generate such pellets, nitrogen-containing BP is chemically conjugated with a MAO coating on hollow Mg-Sr alloys. We demonstrate that BP coated Mg pellet has multiple desired features for OS therapy through in vitro and in vivo studies. At the cellular level, BP coated Mg pellets not only induce apoptosis and necrosis, as well as antitumor invasion of OS cells in the two-dimensional (2D) cell culture environment, but also damage the formation of multicellular tumor spheroids by OS cell lines in the three-dimensional (3D) cell culture environment. At the in vivo level, BP coated Mg pellets can destroy tumors and prevent neoplasm recurrence via synergistic Mg degradation and drug release. It is further suggested that the superior inhibitory effect on OS of our pellet is achieved by inhibiting the mevalonate pathway at the molecular level. Hence, these results collectively show that the BP coated Mg pellet is a promising candidate for future applications in repairing defects after tumor removal in OS therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Bone health and treatments · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (55)

Show source-provided references
1. Translational biology of osteosarcoma10.1038/nrc3838 ↗
3. Novel therapeutic strategies for spinal osteosarcomas10.1016/j.semcancer.2019.05.018 ↗
4. Limb salvage in musculoskeletal oncology10.1016/S1470-2045(03)01114-8 ↗
5. Amputation versus limb-salvage surgery in patients with osteosarcoma: a meta-analysis10.1007/s00268-016-3500-7 ↗
6. Comparative analysis of early follow-up of biologic fixation and cemented stem fixation for femoral tumor prosthesis: biologic fixation and cemented stem fixation for distal femoral tumor prosthesis10.1111/os.12483 ↗
7. Surgical options for children with osteosarcoma10.1016/S1470-2045(05)01734-1 ↗
8. Latest developments in limb-salvage surgery in osteosarcoma10.1586/era.10.225 ↗
9. Osteosarcoma of the mobile spine10.1093/annonc/mdt154 ↗
10. Advances in segmental endoprosthetic reconstruction for extremity tumors: a review of contemporary designs and techniques10.1177/107327481101800303 ↗
11. Hydroxyapatite-coated collars reduce radiolucent line progression in cemented distal femoral bone tumor implants10.1007/s11999-014-4116-6 ↗
12. Bone metastasis: find your niche and fit in10.1016/j.trecan.2018.12.004 ↗
13. Implant-derived magnesium induces local neuronal production of CGRP to improve bone-fracture healing in rats10.1038/nm.4162 ↗
14. Design of biodegradable, implantable devices towards clinical translation10.1038/s41578-019-0150-z ↗
15. Magnesium seeds in the treatment of lymph- and haemangiomata
16. Magnesium seeding in therapy of pediatric hemangioma of the temporal region, lower eyelid and orbit10.1055/s-2008-1035204 ↗
17. The history of biodegradable magnesium implants: a review10.1016/j.actbio.2010.02.028 ↗
18. Cytotoxic effect on osteosarcoma MG-63 cells by degradation of magnesium10.1016/j.jmst.2014.04.010 ↗
19. Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone10.1016/j.actbio.2018.07.028 ↗
20. Blocking HSP90 addiction inhibits tumor cell proliferation, metastasis development, and synergistically acts with zoledronic acid to delay osteosarcoma progression10.1158/1078-0432.CCR-15-1925 ↗
21. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial10.1001/jama.2016.19425 ↗
22. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL10.1002/jbmr.2182 ↗
23. Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment
24. Tuning ligand density to optimize pharmacokinetics of targeted nanoparticles for dual protection against tumor-induced bone destruction10.1021/acsnano.9b04571 ↗
25. Tailoring the degradation and biological response of a magnesium-strontium alloy for potential bone substitute application10.1016/j.msec.2015.09.057 ↗
26. Evaluation of the osteo-inductive potential of hollow three-dimensional magnesium-strontium substitutes for the bone grafting application10.1016/j.msec.2016.12.028 ↗
27. Three-dimensional culture systems in cancer research: focus on tumor spheroid model10.1016/j.pharmthera.2016.03.013 ↗
28. A tumor treatment strategy based on biodegradable BSA@ZIF-8 for simultaneously ablating tumors and inhibiting infection10.1039/C8NH00113H ↗
29. Dual modulation of bone formation and resorption with zoledronic acid-loaded biodegradable magnesium alloy implants improves osteoporotic fracture healing: an in vitro and in vivo study10.1016/j.actbio.2017.10.033 ↗
30. Routine use of zoledronic acid in early-stage breast cancer10.6004/jnccn.2015.0061 ↗
31. Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody10.1016/j.ctrv.2019.05.003 ↗
32. Pre-metastatic niches: organ-specific homes for metastases10.1038/nrc.2017.6 ↗
33. Emerging biological principles of metastasis10.1016/j.cell.2016.11.037 ↗
34. Cell death: a review of the major forms of apoptosis, necrosis and autophagy10.1002/cbin.11137 ↗
35. At the crossroads of apoptosis and autophagy: multiple roles of the co-chaperone BAG3 in stress and therapy resistance of cancer10.3390/cells9030574 ↗
36. Cancer cell membrane-biomimetic nanoplatform for enhanced sonodynamic therapy on breast cancer via autophagy regulation strategy10.1021/acsami.9b10948 ↗
37. Proliferation, cell cycle and apoptosis in cancer10.1038/35077213 ↗
38. Cell-cycle checkpoints and cancer10.1038/nature03097 ↗
39. CDK4/6 inhibition triggers anti-tumour immunity10.1038/nature23465 ↗
40. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs10.1016/j.phrs.2018.11.035 ↗
41. Cell cycle proteins as promising targets in cancer therapy10.1038/nrc.2016.138 ↗
42. Engineering 3D approaches to model the dynamic microenvironments of cancer bone metastasis10.1038/s41413-018-0008-9 ↗
43. The interplay between cell signalling and the mevalonate pathway in cancer10.1038/nrc.2016.76 ↗
44. Represses the mevalonate pathway to mediate tumor suppression10.1016/j.cell.2018.11.011 ↗
45. The mevalonate pathway is a druggable target for vaccine adjuvant discovery10.1016/j.cell.2018.08.070 ↗
46. Zoledronic acid, an FPPS inhibitor, ameliorates liver steatosis through inhibiting hepatic de novo lipogenesis10.1016/j.ejphar.2017.08.010 ↗
47. Zoledronic acid inhibits the RhoA-mediated amoeboid motility of prostate cancer cells10.2174/1568009619666190115142858 ↗
48. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells10.1016/j.canlet.2016.03.004 ↗
49. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers10.1016/j.canlet.2018.10.022 ↗
50. Mevalonate pathway provides ubiquinone to maintain pyrimidine synthesis and survival in p53-deficient cancer cells exposed to metabolic stress10.1158/0008-5472.CAN-19-0650 ↗
51. 3D-printed bioceramic scaffolds: from bone tissue engineering to tumor therapy10.1016/j.actbio.2018.08.026 ↗
52. Abemaciclib is active in preclinical models of Ewing sarcoma via multipronged regulation of cell cycle, DNA methylation, and interferon pathway signaling10.1158/1078-0432.CCR-18-1256 ↗
53. CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signaling10.1126/scisignal.aam8216 ↗
54. Validation of the prognostic value of NF-κB p65 in prostate cancer: a retrospective study using a large multi-institutional cohort of the Canadian prostate cancer biomarker network10.1371/journal.pmed.1002847 ↗
55. Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism10.1016/j.joms.2010.07.017 ↗